| 发明名称 | Luteolin and diosmin/diosmetin as novel STAT3 inhibitors for treating autism | ||
| 摘要 | The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation. | ||
| 申请公布号 | US8778894(B2) | 申请公布日期 | 2014.07.15 |
| 申请号 | US201314046381 | 申请日期 | 2013.10.04 |
| 申请人 | University of South Florida | 发明人 | Tan Jun;Luo Deyan;Shytle Roland Douglas |
| 分类号 | A01N43/04;A61K31/70;A01N43/16;A61K31/35 | 主分类号 | A01N43/04 |
| 代理机构 | Smith & Hopen, P. A. | 代理人 | Lawson Michele L.;Smith & Hopen, P. A. |
| 主权项 | 1. A method of reducing the risk of developing autism in a patient due to exposure of the patient in utero to elevated levels of IL-6 from the patient's mother-comprising: inhibiting activation of STAT3 in both the patient and the patient's mother by administering a therapeutically effective amount of a flavonoid selected from the group consisting of luteolin, diosmin, and diosmetin to the patient's mother during pregnancy; wherein STAT3 in the patient and the patient's mother is activated by elevated levels of IL-6 from the patient's mother. | ||
| 地址 | Tampa FL US | ||